ArticleThe oncologist2022

Anlotinib Combined with Toripalimab as Second-Line Therapy for Advanced, Relapsed Gastric or Gastroesophageal Junction Carcinoma.

Man Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.